Regulatory August 23, 2023

Correction: Lipidor AB (publ) publishes interim report for Q2 2023

STOCKHOLM, Sweden, 23 August 2023 – In Lipidor's interim report for the second quarter 2023, published today at 08:30, incorrect figures were reported for the comparison period Jan-Jun 2022. Instead, Jan-Jun 2021 figures were included.

The corrected quarterly report is available on the company's website lipidor.se and in the attached pdf.

To read the quarterly report (in Swedish) click here: https://lipidor.se/lipidor-ab-delarsrapport-q2-2023/

Publication

The information was provided for publication by Lipidor’s CEO on 23 August 2023 at 11.18pm (CEST).

For more information, please contact
Lipidor AB (Reg. No. 556779-7500)
Ola Holmlund, CEO
Phone: +46 72 50 70 369
E-mail: ola.holmlund@lipidor.se
c/o Ekonomistubben
Box 55931
102 16 Stockholm

Certified adviser
Erik Penser Bank AB
Apelbergsgatan 27, Box 7405
103 91 Stockholm
Homepage: www.penser.se

About Lipidor AB
Lipidor AB (Nasdaq First North Growth Market: LIPI) (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.

Attachments
Lipidor AB Delårsrapport Q2 2023 V2

Lipidor AB Delårsrapport Q2 2023 V2